Accordingly, anti-vascular endothelial growth factor) monoclonal antibodies have been proposed, in preclinical settings based on the upregulation of these mediators in Hg-induced endothelial dysfunctions. The gene discussed is VEGFA; the disease is endothelial dysfunction.